tbuckley/cabot-search huggingface dataset:
Abstract 17390: Association of Arterial Stiffness With Risk of Heart Failure and its Subtypes Among Community-dwelling Participants of the HealthABC Study
Authors: Ambarish Pandey, Hassan Khan, Javed Butler, Jarett Berry
Journal: Circulation (2016)

Introduction: Higher arterial stiffness is associated with increased risk of adverse CV outcomes such as MI and stroke. However, the association between arterial stiffness and risk of HF and its su...
Increased risk of second primary malignancies in patients with mycosis fungoides: A single-center cohort study
Authors: Amrita Goyal, Daniel O'Leary, Kavita Goyal, Nathan Rubin, Kimberly Bohjanen, Maria Hordinsky, Steven T. Chen, Lyn M. Duncan, Georgios Pongas, Aleksandr Lazaryan
Journal: Journal of the American Academy of Dermatology (2019)
AB1355-HPR A SYSTEMATIC LITERATURE REVIEW (SLR) ON NURSING SENSITIVE OUTCOMES IN SYSTEMIC SCLEROSIS (SSC)
Authors: Khadija El Aoufy, Laura Rasero, Guya Piemonte, Gianni Virgili, Serena Guiducci, Cosimo Bruni, Silvia Bellando Randone, Marco Matucci-Cerinic
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> <b>SSc</b> affects significantly patients functionality and Quality of Life (QoL). Specific Nursing Sensitive Outcomes (<b>NSOs</b>) still need to be established in SSc. <h3>Objectives</h3> This SLR was aimed at identifying NSOs in SSc patients and the related screening tools. <h3>Methods</h3> Medline, CINHAL, EMBASE and PsycINFO were searched to identify relevant studies. Experimental and observational studies that reported nursing interventions and NSOs were included. All potentially eligible studies were read in full text and examined against the selection criteria previously listed. Quality assessment was carried out through <i>Critical Appraisal Skills Programme</i> tools; and, the <i>OMERACT</i> (<i>Outcome Measures in Rheumatology</i>) comprehensive conceptual framework for health was used to contextualise and summarize findings. <h3>Results</h3> 7015 records were screened for title and abstract, 39 full-text were identified and assessed. Eleven studies were included in this SLR. For the core area "<i>pathophysiological manifestations</i>" 4 domains (healths status, digital ulcers, clinical efficacy and fatigue), and, for the core area- "<i>impact on life</i>"- 5 domains were found (functionality, patient knowledge, patient satisfaction, psychological status and quality of life). Thus, NSOs identified were physical function and parameters, health events, upper limb functionality, patients knowledge of disease complications, degree of self-management, need for nursing instructions, self-efficacy, health efficacy, psychological state, depressive mood and QoL. <h3>Conclusion</h3> <b>T</b>he results identify outcomes that may allow the structuring of a preliminary behavioural flow chart for nursing SSc case management. Further researches are warranted to examine the multidimensional and complex role of nursing in SSc management. Flow chart of the SLR: <h3>Disclosure of Interests</h3> Khadija El Aoufy: None declared, Laura Rasero: None declared, Guya Piemonte: None declared, Gianni Virgili: None declared, Serena Guiducci: None declared, Cosimo Bruni: None declared, Silvia Bellando Randone: None declared, Marco Matucci-Cerinic Grant/research support from: Actelion, MSD, Pfizer, BMS, Chemomab, Sanipedia, Speakers bureau: Actelion, BMS; MSD, Janssen
Abstract 15838: Oxidative Stress is Related to Increased Sodium-Aldosterone Product and Left Ventricular Dysfunction in Resistant Hypertension
Authors: Brittany Butts, Thomas S Denney, Inmaculada B Aban, David A Calhoun, Louis J Dell'Italia
Journal: Circulation (2017)

Introduction: Resistant hypertension (R-HTN) is associated with hyperaldosteronism that responds to either salt restriction or aldosterone receptor blockade. Endothelial dysfunction is an important...
Timing of HPV16-E6 antibody seroconversion before OPSCC: findings from the HPVC3 consortium
Authors: A.R. Kreimer, A. Ferreiro-Iglesias, M. Nygard, N. Bender, L. Schroeder, A. Hildesheim, H.A. Robbins, M. Pawlita, H. Langseth, N.F. Schlecht, L.F. Tinker, I. Agalliu, S.W. Smoller, E. Ness-Jensen, K. Hveem, G. D’Souza, K. Visvanathan, B. May, G. Ursin, E. Weiderpass, G.G. Giles, R.L. Milne, Q. Cai, W.J. Blot, W. Zheng, S.J. Weinstein, D. Albanes, N. Brenner, J. Hoffman-Bolton, R. Kaaks, A. Barricarte, A. Tjønneland, C. Sacerdote, A. Trichopoulou, R.C.H. Vermeulen, W.-Y. Huang, N.D. Freedman, P. Brennan, T. Waterboer, M. Johansson
Journal: Annals of Oncology (2019)

Human papillomavirus type 16 (HPV16)-E6 antibodies are detectable in peripheral blood before diagnosis in the majority of HPV16-driven oropharyngeal squamous cell carcinoma (OPSCC), but the timing of seroconversion is unknown.
Iron deficiency anemia
Authors: Martina U. Muckenthaler
Journal: HemaSphere (2019)

Learning goals The aim of this educational session is to generate novel insight into frequent pathologies caused by a misregulation of the hepcidin/ferroportin system novel approaches to oral iron treatment diagnosis of iron-related disorders Introduction Systemic iron homeostasis is maintained by the iron-regulated peptide hormone hepcidin and its target receptor, the iron exporter ferroportin. The hepcidin/ferroportin regulatory axis prevents diseases of iron overload (ie, Hereditary hemochromatosis, thalassemia) or iron deficiency (ie, anemia). In this session, we will discuss pathologies underlying these frequent disorders and dissect mechanisms that cause functional or absolute iron overload or deficiency. We will explore novel approaches to oral iron treatment, the value of hepcidin as a diagnostic marker and how novel therapeutics just entering clinical trials modulate plasma iron availability via the hepcidin/ferroportin regulatory system. This session provides an exciting example for how knowledge derived from basic research can be translated into the clinic.
AB0369 SAFETY, EFFICACY AND RETENTION RATE OF BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (BDMARDS) IN ASSOCIATION WITH DENOSUMAB: COMPARISON OF COMBINATION AND MONO-THERAPY REGIMENS
Authors: Cosimo Bruni, Cosimo Cigolini, Giulia Tesei, Francesca Bartoli, Ginevra Fiori, Maria Letizia Conforti, Silvia Bellando Randone, Serena Guiducci, Marco Matucci-Cerinic
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Osteoporosis is a frequent complication of rheumatic muscle-skeletal diseases (RMD), with high impact from steroid treatment. It is known that bDMARD impact positively on patients' prognosis and this is also known for Denosumab, a monoclonal antibody for osteoporosis. The combination treatment with two monoclonal antibodies, bDMARD &amp; denosumab, has addressed the problem of safety and efficacy, with incomplete answers from the available literature. Objectives: to evaluate the impact of the combination treatment bDMARD+Denosumab (COMBO group), compared to mono-therapy with bDMARD (MONO group), on clinical efficacy, safety and treatment retention of bDMARD in patients with RMD. <h3>Methods</h3> RMD patients treated with COMBO therapy where enrolled from a single centre rheumatology unit; for each case, at least one MONO therapy control (matched per age±5 years, sex, bDMARD, RMD, without osteoporosis) was enrolled. Data on clinical efficacy (3-points Likert scale for physician and patient – improved/stable/worse), safety (locl reaction, serious and non-serious adverse events) and bDMARD treatment retention at 12, 18 and 24 months. <h3>Results</h3> Out of 129 eligible patients, 77 were enrolled in the protocol: 49 in the MONO and 28 in the COMBO group. The two groups were different of age (slightly higher in the COMBO group), for tender joint count, erythrocyte sedimentation rate and c-reactive protein (higher in the MONO group). Efficacy analysis showed higher percentage of clinical improvement at 12 months in the MONO group at 12 months, being not significant at 18 and 24 months (possibly explained by a different disease activity at baseline visit, corresponding to the overlap of denosumab on top of bDMARD in the COMBO and to the initiation of bDMARD in the MONO group). Between the 2 groups, no difference about safety and retention rate was found. Conclusion: the efficacy of COMBO treatment is similar to MONO therapy. Moreover, the data show that also safety and retention rate are similar. Therefore, the COMBO treatment with 2 different monoclonals can be safely employed in the treatment of RMDs and osteoporosis. <h3>Disclosure of Interests</h3> Cosimo Bruni: None declared, Cosimo Cigolini: None declared, Giulia Tesei: None declared, Francesca Bartoli: None declared, Ginevra Fiori: None declared, Maria Letizia Conforti: None declared, Silvia Bellando Randone: None declared, Serena Guiducci: None declared, Marco Matucci-Cerinic Grant/research support from: Actelion, MSD, Pfizer, BMS, Chemomab, Sanipedia, Speakers bureau: Actelion, BMS; MSD, Janssen
AB0594 THE CLINICAL SPECTRUM OF HENOCH-SCHÖNLEIN PURPURA IN CHILDREN: A PROSPECTIVE SINGLE-CENTER STUDY
Authors: Şerife Gül Karadağ, Hafize Emine Sonmez, Ayşe Tanatar, Mustafa Çakan, Figen Çakmak, Nuray Aktay Ayaz
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Henoch–Schönlein purpura (HSP) is the most common vasculitis of children. Predicting the risk factors at the time of diagnosis for systemic involvement may facilitate the management of the disease. <h3>Objectives</h3> The aim of this study is to evaluate the demographic and clinic findings of patients with HSP and also to determine predictive factors for assessing the development of gastrointestinal system (GIS) and renal involvement. <h3>Methods</h3> This study was performed prospectively among children with HSP who are under 18 years of age and being followed-up in the Pediatric Rheumatology Unit of Health Sciences University Kanuni Sultan Süleyman Training and Research Hospital between January 2016 and January 2018. <h3>Results</h3> A total of 265 patients, 137 boys (51.7%) and 128 girls (48.3%) were involved to the study. The mean ± standard deviation of age at the diagnosis was 7.5±3.2. The most common disease onset season was spring (31.7%). The rate of arthritis, GIS involvement and renal involvement was 54%, 51.3% and 29.1% respectively. GIS bleeding was more frequent in males than females (p=0.007). Boys over 7 years of age had significantly more common GIS bleeding (p=0.04). Intussusception, relapse and serious GIS involvement requiring hospitalization and steroid treatment were highly associated with severe renal involvement. <h3>Conclusion</h3> Intussusception, relapse and serious GIS involvement requiring hospitalization and steroid treatment were highly associated with severe renal involvement. We recommend at least 2 years follow-up for not overlooking renal involvement of HSP <h3>References</h3> [1] Yang YH, Hung CF, Hsu CR, Wang LC, Chuang YH, Lin YT, Chiang BL (2005) A nationwide survey on epidemiological characteristics of childhood Henoch-Schonlein purpura in Taiwan. Rheumatology (Oxford) 44 (5):618-622. doi:10.1093/rheumatology/keh544 [2] Wang K, Sun X, Cao Y, Dai L, Sun F, Yu P, Dong L (2018) Risk factors for renal involvement and severe kidney disease in 2731 Chinese children with Henoch-Schonlein purpura: A retrospective study. Medicine (Baltimore) 97 (38):e12520. doi:10.1097/MD.0000000000012520 <h3>Acknowledgement</h3> None <h3>Disclosure of Interests</h3> None declared
PS1592 EFFECT OF ANAEMIA ON MUSCLE OXYGEN SATURATION DURING EXERCISE
Authors: P. Crispin
Journal: HemaSphere (2019)

Background: Transfusion of red cells in chronic hypoproliferative anemia aims to improve function in the recipients. Few studies examine functional measures as a trigger for transfusion, in part due to limited tools to functionally assess anemia. Aims: To evaluate the effect of anemia on muscle oxygen saturation (SmO 2 ) during exercise. Methods: Haematology patients with and without anaemia and normal controls were invited to participate. Each undertook a six minute walk test (6MWT) with continuous gastrocnemius SmO 2 monitoring. Patients with a significant change in haemoglobin (such as due to transfusion) were invited to repeat the investigation, up to three subsequent times. Changes in SmO 2 were examined in the pooled results of controls, key parameters identified and then extracted from individual participants. The correlation of each parameter with 6WWT distance, as a measure of functional capacity, was evaluated by linear and multifactorial regression. Participants with repeated 6MWT before and after hemoglobin changes were compared with paired T tests. Results: There were 73 participants, including 28 with known or presumed normal haemoglobin levels, undertaking 93 walking tests. Examination of control participant curves identified the SmO 2 parameters at baseline, nadir and plateau levels, with the fall in SmO 2 defined as the difference between baseline and nadir SmO 2 . In univariate analysis the distance walked correlated with haemoglobin (r = 0.47, p &lt; 0.001), baseline SmO 2 , (r = 0.34, p = 0.001), nadir SmO 2 (r = 0.26, p = 0.013) and the plateau SmO 2 (r = 0.4, p = 0.001) however these were not independent cofactors in multivariate analysis. The fall in SmO 2 did not correlate with the distance walked. There were 17 paired sets of walks with changed hemoglobin levels. An improved 6MWT distance was observed with increased hemoglobin concentration ( p &lt; 0.01), but there was no significant improvement in SmO2 values in individuals with higher haemoglobin concentrations. Summary/Conclusion: Anemia is associated with reduced function as measured by 6MWT distance and reduced SmO 2 before and during exercise. The absolute fall in SmO 2 during submaximal exercise was not increased by anemia. This may be due to decreased rate of oxygen demand with shorter walk distances seen in anemia. Although SmO 2 values are associated with the functional impairment of anemia, they are not superior to currently used triggers.
SAT0143 SAFETY AND EFFECTIVENESS OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN ELDERLY PATIENTS WITH RHEUMATOID ARTHRITIS
Authors: Raquel Freitas, Joao Eurico Fonseca, Joaquim Polido-Pereira, Nathalie Madeira, Luís Cunha Miranda, Miguel Bernardes, Bruno Miguel Fernandes, Flavio Costa, Mariana Santiago, Agna Neto, Soraia Azevedo, João Madruga Dias, Mara Couto, Graça Sequeira, Maria Jose Santos
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Elderly population with rheumatoid arthritis (RA) is increasing. However, these patients are frequently excluded from clinical trials and data on effectiveness and safety of biologic Disease-Modifying Antirheumatic Drug (bDMARD) is scarce. <h3>Objectives:</h3> To assess the persistence of 1<sup>st</sup> bDMARD and the effectiveness and safety of bDMARD among elderly (≥65 years). <h3>Methods:</h3> Prospective multicenter cohort-study of RA patients starting a 1<sup>st</sup> bDMARD registered at Reuma.pt. Demographic and disease characteristics, comorbidities, medications, disease activity at baseline and follow up (3, 6 and 12 months) and adverse events (AE) were compared between elderly and adult (&lt;65 years) patients. Treatment persistence was estimated using Kaplan-Meier analysis. Effectiveness was measured as EULAR crude response rates, LUNDEX corrected, and adjusted for baseline characteristics. <h3>Results:</h3> 2400 patients were included, of which 486 aged ≥65 years (table 1). Crude median persistence in bDMARD was 19.7 months (95%CI 14-25) in adults and 14.5 (95%CI 3-26) in elderly patients (log rank test, p=0.46) (figure 1). EULAR response (crude and LUNDEX corrected) was similar in the two groups at 3 and 6 months (figure 2). After adjustment for baseline characteristics, response rate was inferior in elderly at 12 months (p=0.01). There were 697 AE reported. Except for infections, more common in elderly patients (p=0.03), the rates of severe AE, opportunistic infection, allergic reactions, cancer or hospitalizations were similar in the two groups, as well as the time to 1<sup>st</sup> AE occurrence (figure 2). <h3>Conclusion:</h3> Our findings showed that persistence of 1<sup>st</sup> bDMARD was similar in adults and elderly RA patients. Though elderly had more severe disease and comorbidities at baseline, bDMARD treatment was equally effective and safe in the short term. However, it is necessary to consider the greater risk of infection in elderly when prescribing a biologic. <h3>Disclosure of Interests:</h3> None declared
PB1759 DNMT3A MUTATION IS NOT RELATED WITH UNFAVORABLE CLINICAL OUTCOME IN ACUTE MYELOID LEUKEMIA PATIENTS
Authors: Y.K. Lee, J. Lee, K. Jeon, M. Kim, B. Han, H.J. Kim
Journal: HemaSphere (2019)

Background: Mutation in DNMT3A (DNA methyltransferase 3A) has been identified as a key factor in the development of hematological malignancy. While some previous reports have suggested that DNMT3A mutation is related with negative outcome in acute myeloid leukemia (AML) patients, the clinical implication and prognostic significance of DNMT3A mutation in AML is still debated. Aims: We intended to investigate the incidence of DNMT3A gene mutation and its association with clinical and laboratory findings and prognosis in Korean AML patients. Methods: From 2012 to 2018, we enrolled forty‐nine patients diagnosed with AML without recurrent genetic abnormalities. We performed Sanger sequencing to analyze DNMT3A mutation using residual bone marrow samples. We also collected other laboratory data and clinical information via electronic medical records. Results: We found DNMT3A mutations in 6 out of 49 AML patients (12.2%). Five patients had the R882H mutation, and one patient the R882C mutation. There was no significant difference in age, complete blood cell count (CBC) parameters, or bone marrow (BM) blast % between the groups with and without DNMT3A mutations. The portion of patients older than 60 years was smaller in DNMT3A mutation positive group (33.3% vs. 60.5%, p = 0.381). DNMT3A mutation group showed higher rate of complete remission (CR) (50% vs. 27.9%, p = 0.353), shorter period to CR (1.1 (CI 1.1 – 1.2) months vs. 1.2 (CI 1.0 – 2.8) months, p = 0.613), and lower relapse rate after CR (0% vs. 41.7%, p = 0.505) than DNMT3A mutation negative group although the difference was not statistically significant. In the survival analysis, the median overall survivals (OS) were 29.0 (CI 5.5 – 52.4) months for DNMT3A mutation positive group and 10.8 (CI 0.5 – 21.0) months for DNMT3A mutation negative group. The median progression free survivals (PFS) were 29.0 months (CI 5.5 – 52.5 months) for DNMT3A mutation positive group and 8.0 months (CI 0.0 – 16.3 months) for DNMT3A mutation negative group. However, the effect of DNMT3A mutation on OS and PFS was not statistically significant ( p = 0.814 and p = 0.528, respectively). In a multivariate analysis, the only independent predictive factors for survival were age (HR: 1.027, p = 0.001) and BM blast % (HR: 1.017, p = 0.016). DNMT3A mutation, sex, and CBC parameters were not independent predictors of survival. Figure 1. Kaplan‐Meier overall survival analysis (A) and progression‐free survival analysis (B) comparing between the groups with and without DNMT3A mutation. Summary/Conclusion: The incidence of DNMT3A mutation was 12.2% in Korean AML patients. DNMT3A mutation tended to be related with favorable outcome although statistically insignificant. This statistical insignificance might be due to the small sample size. Considering all, our results at least provide support for the view that DNMT3A mutations is not an unfavorable prognostic factor in AML patients. image
PB2445 PRE‐TRANSFUSION IMMUNOHEMATOLOGY TESTING INTERFERENCE WITH DARATUMUMAB: PRELIMINARY EXPERIENCE FROM THE FIRST PATIENTS TREATED AT ASST GOM NIGUARDA
Authors: I. Cuppari, R. Crocchiolo, E. Boiani, A. Cafro, P. Bertazzoni, M. Soldarini, M. T. Pugliano, E. Volpato, S. Rossini
Journal: HemaSphere (2019)

Background: Daratumumab is a human anti‐CD38 monoclonal antibody approved for the treatment of relapsed or refractory multiple myeloma (MM). Due to the physiological presence of the antigen CD38 on the red blood cell (RBC) membrane, Daratumumab (DARA) inteferes with the classical pre‐transfusion tests, impairing the identification of potential auto‐ or alloantibodies whenever present. The duration of this interference has been reported to be of 2‐6 months after the last DARA administration [Oostendorp M, Transfusion 2015]. Aims: The present analysis aims at evaluating the duration of DARA‐related pre‐transfusion testing interference after the end of treatment at our Center, in order to better define an optimal strategy to assign compatible packed RBCs for transfusion therapy. Methods: According to our policy, all patients were typed for AB0, full Rh phenotype, K/k, direct/indirect antiglobulin tests and extended sierological RBCs typing before starting with DARA [2016 SIMTI recommendations]; the identification of compatible packed RBCs was obtained after crossmatching using dithiothreitol‐treated patient's blood sample. Results: From October 2017, a total of n = 7 MM patients received DARA at a median age of 68y (range: 50‐79); median number of previous therapeutic lines was 3 (range: 1‐7) and the median number of weekly administrations was 7 per patient (range: 1‐12). Two patients are still receiving DARA (1 and 12 administrations respectively). As expected, both direct and indirect antiglobulin tests were positive for all patients; moreover, one patient had also a well‐identified allo anti‐D antibody. Among the n = 5 ongoing patients, n = 4 are evaluable because they underwent the subsequent pre‐transfusion tests after the end of DARA treatment: n = 1 still presents interference 50 days after the end of DARA whereas interference disappeared in n = 3 patients at 48, 65 and 111 days after the last treatment. Summary/Conclusion: Our preliminary data confirm the persistence of DARA‐related pre‐transfusion testing interference after the end of treatment for a median period of 2 months in this cohort of MM patients treated at our Institution. Futher follow‐up and the analysis of additional patients in the next future will allow to better determine the duration of interference; we believe these data are worthy of note due to increasing use of DARA, even for other clinical situations [Chapuy CI, NEJM 2018; Kwun JEB, Am J Transplant 2017]
Pregnant women whose waters break can opt to continue to 37 weeks, says RCOG
Authors: Elisabeth Mahase
Journal: BMJ (2019)

Pregnant women whose waters break early (from 24 weeks) but don’t go into labour should be given the choice to continue with the pregnancy until 37 weeks, as long as there are no signs of infection or complications, say new guidelines.1

The updated recommendation from the Royal College of Obstetricians and Gynaecologists, launched at the college’s world congress this week, said that continuing the pregnancy closer to term could reduce the risk of problems linked to premature …